PMCB PharmaCyte Biotech, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1157075 · Fiscal year ends 04/30
Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,334.7%
TTM EPS YoY-3,566.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-45.4%
ROA-39.5%
ROIC (approx.)-27.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets18.8%
Debt / equity0.00x
Current ratio40.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.24x
Accruals ratio-29.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q12026-07-31 | 2026Q4*2026-04-30 | 2026Q32026-01-31 | 2026Q22025-10-31 | 2026Q12025-07-31 | 2025Q4*2025-04-30 | 2025Q32025-01-31 | 2025Q22024-10-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $60,000 | $61,946 | $93,113 | $141,085 | $95,157 | $126,734 | $118,196 | $97,470 |
| SG&A expense | $946,708 | $899,882 | $2.02M | $1.23M | $753,148 | $3.45M | $842,056 | $1.01M |
| Operating income | -$1.01M | -$2.51M | -$2.12M | -$1.38M | -$848,305 | -$1.04M | -$960,252 | -$1.11M |
| Income tax | $0 | — | — | — | $0 | — | — | — |
| Net income | -$5.08M | -$4.39M | $746,860 | -$7.42M | -$8.36M | $11.75M | -$3.05M | -$1.47M |
| EPS (basic) | -0.54 | — | -0.17 | -1.24 | -1.23 | — | -0.44 | -0.39 |
| EPS (diluted) | -0.54 | — | -0.17 | -1.24 | -1.23 | — | -0.44 | -0.39 |
| Weighted avg. shares (diluted) | 10.74M | — | 9.26M | 6.80M | 6.80M | — | 6.96M | 7.64M |
| Balance sheet | ||||||||
| Cash & equivalents | $17.74M | $18.60M | $20.17M | $15.41M | $13.18M | $15.17M | $16.38M | $20.84M |
| Short-term investments | $99,462 | $254,010 | $372,251 | $201,190 | $261,853 | $366,316 | $372,632 | — |
| Current assets | $30.97M | $37.42M | $20.70M | $23.02M | $19.11M | $22.38M | $16.96M | $21.33M |
| Intangibles | — | $0 | $1.55M | $1.55M | $1.55M | $1.55M | $1.55M | $1.55M |
| Total assets | $36.71M | $46.75M | $55.87M | $55.98M | $45.11M | $55.17M | $43.83M | $55.10M |
| Current liabilities | $768,682 | $826,424 | $1.68M | $1.58M | $1.06M | $2.91M | $1.19M | $4.78M |
| Total liabilities | $6.90M | $11.77M | $16.47M | $19.42M | $1.52M | $3.28M | $3.58M | $11.65M |
| Shareholders' equity | $27.51M | $33.29M | $38.11M | $35.24M | $43.59M | $51.89M | $40.25M | $43.45M |
| Shares outstanding | 10.74M | 10.74M | 10.74M | — | 6.80M | 6.80M | 6.90M | 7.03M |
| Cash flow statement | ||||||||
| Operating cash flow | -$780,894 | -$1.39M | -$786,848 | -$979,523 | -$1.99M | -$1.04M | -$509,893 | -$1.05M |
| Investing cash flow | — | $0 | $5.00M | -$3.00M | $0 | $0 | $0 | $0 |
| Financing cash flow | -$83,399 | -$169,818 | $543,779 | $6.21M | $0 | -$171,543 | -$3.95M | -$10.74M |
| Stock-based compensation | — | $0 | $771,516 | $60,492 | $60,492 | $0 | $72,861 | $119,155 |
| Share buybacks | — | $0 | $401,625 | $0 | $0 | $171,543 | $225,025 | $1.40M |
Free plan shows the latest 8 periods; Pro shows all 65 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.